### Citation

### As Published
http://dx.doi.org/10.1523/JNEUROSCI.0672-16.2016

### Publisher
Society for Neuroscience

### Version
Final published version

### Accessed
Sat Feb 09 06:13:56 EST 2019

### Citable Link
http://hdl.handle.net/1721.1/110232

### Terms of Use
Creative Commons Attribution 4.0 International License

### Detailed Terms
http://creativecommons.org/licenses/by/4.0/
Negative Allosteric Modulation of mGluR5 Partially Corrects Pathophysiology in a Mouse Model of Rett Syndrome

Jifang Tao,1,2 Hao Wu,3,4,5 Amanda A. Coronado,1,2 Elizabeth de Laittre,1,2 Emily K. Osterweil,6 Yi Zhang,3,4,5 and Mark F. Bear1,2

1Picower Institute for Learning and Memory and 2Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, 3Howard Hughes Medical Institute, Boston, Massachusetts 02115, 4Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, Massachusetts 02115, 5Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, and 6Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom

Rett syndrome (RTT) is caused by mutations in the gene encoding methyl-CpG binding protein 2 (MECP2), an epigenetic regulator of mRNA transcription. Here, we report a test of the hypothesis of shared pathophysiology of RTT and fragile X, another monogenic cause of autism and intellectual disability. In fragile X, the loss of the mRNA translational repressor FMRP leads to exaggerated protein synthesis downstream of metabotropic glutamate receptor 5 (mGluR5). We found that mGluR5- and protein-synthesis-dependent synaptic plasticity were similarly altered in area CA1 of Mecp2 KO mice. CA1 pyramidal cell-type-specific, genome-wide profiling of ribosome-bound mRNAs was performed in wild-type and Mecp2 KO hippocampal CA1 neurons to reveal the MeCP2-regulated “translatome.” We found significant overlap between ribosome-bound transcripts overexpressed in the Mecp2 KO and FMRP mRNA targets. These tended to encode long genes that were functionally related to either cytoskeleton organization or the development of neuronal connectivity. In the Fmr1 KO mouse, chronic treatment with mGluR5-negative allosteric modulators (NAMs) has been shown to ameliorate many mutant phenotypes by correcting excessive protein synthesis. In Mecp2 KO mice, we found that mGluR5 NAM treatment significantly reduced the level of overexpressed ribosome-associated transcripts, particularly those that were also FMRP targets. Some Rett phenotypes were also ameliorated by treatment, most notably hippocampal cell size and lifespan. Together, these results suggest a potential mechanistic link between MeCP2-mediated transcription regulation and mGluR5/FMRP-mediated protein translation regulation through coregulation of a subset of genes relevant to synaptic functions.

Key words: autism; fragile X; intellectual disability; metabotropic glutamate receptor; Rett syndrome; synaptic protein synthesis

Significance Statement
Altered regulation of synaptic protein synthesis has been hypothesized to contribute to the pathophysiology that underlies multiple forms of intellectual disability and autism spectrum disorder. Here, we show in a mouse model of Rett syndrome (Mecp2 KO) that metabotropic glutamate receptor 5 (mGluR5)- and protein-synthesis-dependent synaptic plasticity are abnormal in the hippocampus. We found that a subset of ribosome-bound mRNAs was aberrantly upregulated in hippocampal CA1 neurons of Mecp2 KO mice, that these significantly overlapped with FMRP direct targets and/or SFARI human autism genes, and that chronic treatment of Mecp2 KO mice with an mGluR5-negative allosteric modulator tunes down upregulated ribosome-bound mRNAs and partially improves mutant mouse phenotypes.

Introduction
Accumulating evidence suggests that aberrant synaptic protein synthesis may contribute to the pathophysiology underlying autism spectrum disorder (ASD) and intellectual disability (ID) (Kelleher and Bear, 2008). Synaptic control of local protein synthesis can be assayed in animal models by the study of synaptic...
long-term depression (LTD) induced by activation of metabotropic glutamate receptor 5 (mGluR5) (Huber et al., 2000, Huber et al., 2001). Studies over the past 15 years have shown that protein-synthesis-dependent mGluR-LTD is altered in multiple mouse models of ASD and ID, including those for fragile X, tuberous sclerosis, CYFIP1 and SYNGAP1 haplo-insufficiency, and chromosome 16p11.2 microdeletion (Huber et al., 2002, Auerbach et al., 2011, Bozdagi et al., 2012, Barnes et al., 2015, Tian et al., 2015). These results support the notion that aberrant regulation of synaptic protein synthesis represents a point of convergence for many varied gene mutations that manifest behaviorally as ASD and ID.

Rett syndrome (RTT), affecting 1 in 10,000 females, is a severe developmental disorder caused by mutations in an X-chromosome gene encoding methyl-CpG binding protein 2 (MECP2). RTT patients have seemingly normal development for the first 6–18 months before entering the stage of regression. Major symptoms include ASD, deceleration of head growth, loss of speech and purposeful hand movements, gait abnormalities, and irregular breathing patterns. The disease is rare in males because hemizygous mutation of MECP2 leads to early lethality. Postmortem studies show that RTT is not a neurodegenerative disorder, but neurons in patients’ brains are smaller in size and more densely packed (for review, see Chahrour and Zoghbi, 2007). Heterozygous female mice with Mecp2 mutation exhibit relatively subtle symptoms until 20 weeks or older, with varied symptom onset age (Samaco et al., 2013). In contrast, hemizygous Mecp2 KO male (Mecp2−/−) mice recapitulate many clinically relevant symptomatic features at an earlier age, including locomotor deficits, irregular breathing with apneas, reduced neuronal soma size, premature death, and severe learning and memory impairment. Therefore, male Mecp2 KO mice are often used as a functionally relevant disease model for revealing the underlying pathophysiology of RTT (Chen et al., 2001, Guy et al., 2001).

MeCP2 selectively recognizes and binds to methylated cytosines in the genome and acts as a major effector protein for this epigenetic DNA modification (Lewis et al., 1992, Skene et al., 2010, Guo et al., 2014, Gabel et al., 2015). Although overall gene expression appears to be only modestly dysregulated in the absence of MeCP2 (Tudor et al., 2002, Jordan et al., 2007, Chahrour et al., 2008, Ben-Shachar et al., 2009, Gabel et al., 2015), MeCP2 was found recently to preferentially repress the transcription of many long genes associated with relatively high levels of intragenic non-CpG methylation (Sugino et al., 2014, Chen et al., 2015, Gabel et al., 2015). Moreover, MeCP2 may also regulate microRNA expression and thereby exert an additional layer of transcription/translation regulation (Szluchwach et al., 2010, Wu et al., 2010).

Because transcription and translation are in general tightly coupled to allocate cellular resources efficiently (Li et al., 2014), we set out to test the hypothesis that loss of MeCP2 as a transcription repressor may lead to downstream translational dysregulation of a cohort of mRNAs that are under tight translational control by an mGluR5/FMRP pathway. In the current study, using integrated approaches of electrophysiology, biochemistry, genomics, and behavioral analyses, we find that in early symptomatic Mecp2 KO mice, hippocampal mGluR-LTD is protein synthesis independent and protein translation is abnormal, with an increase in ribosome-associated mRNAs for long genes. Furthermore, we provide evidence that many MeCP2-repressed and FMRP-bound mRNAs that are aberrantly upregulated in Mecp2 KO may be tuned down by treatment with a negative allosteric modulator of mGluR5, which suggests a mechanistic link between MeCP2-mediated transcription repression and FMRP-mediated translation regulation. Finally, we demonstrate that pharmacological modulation of the mGluR5 signaling pathway partially ameliorates a subset of RTT phenotypes.

Materials and Methods

Animals. Mecp2 KO mice (Mecp2tm1.1bird, 003890; The Jackson Laboratory) and WT littermates were maintained on a C57BL/6 background by breeding Mecp2−/− females with WT males from Charles River Laboratories (strain code: 027). The Cck-bacTRAP (GM39) line was provided by Dr. Nathaniel Heintz of The Rockefeller University. In this mouse, EGFP fused to the ribosomal protein L10a was inserted in the bacterial artificial chromosome (BAC) in such a way that expression was driven by the cholecystokinin (Cck) promoter. All animal experimentation was done in accordance with National Institutes of Health and Massachusetts Institute of Technology guidelines. All experiments were performed on littermate WT and Mecp2 KO mice with the experimenter blinded to genotype.

Hippocampal slice physiology. Experiments were done as described previously (Auerbach et al., 2011). Acute hippocampal slices (350 μm) were prepared using a vibrisscor from postnatal day 30 (P30) to P35 mice in ice-cold dissection buffer containing the following (in mM): NaCl 87, sucrose 75, KCl 2.5, NaH2PO4 1.25, NaHCO3 25, CaCl2 0.5, MgSO4 7, ascorbic acid 1.3, and t-glucose 10 (saturated with 95% O2/5% CO2). Immediately after slicing, the CA3 region was removed. Slices were recovered in artificial CSF (ACSF) containing the following (in mM): NaCl 124, KCl 5, NaH2PO4 1.23, NaHCO3 26, CaCl2 2, MgCl2 1, and t-glucose 10 (saturated with 95% O2/5% CO2) at 32.5°C for at least 3 h before recording. Field EPSPs (fEPSPs) were evoked by stimulation of the Schaffer collaterals and recorded from CA1 stratum radiatum. Chemical LTD was induced by applying S-3,5-dihydroxyphenylglycine (DHPG, 30 μM; Sigma-Aldrich) for 5 min (Huber et al., 2001). For experiments with cycloheximide treatment, slices were incubated in ACSF containing 60 μM cycloheximide (Sigma-Aldrich) throughout the recording. The initial slope of the fEPSP was used to assess synaptic strength. Data were normalized to the baseline response and are presented as mean ± SEM. LTD was calculated by comparing the average response 55–60 min after DHPG application with the average of the last 5 min of baseline. Waveforms shown are from all traces averaged from all animals at the time points indicated. Genotype and drug effect were analyzed using two-way ANOVA.

Immunoblotting. Hippocampal slices were lysed in Laemmli buffer and equal amounts of protein were loaded and resolved in SDS-PAGE and transferred onto nitrocellulose membrane. Total protein levels were quantified by MemCode reversible protein stain (Pierce). The following antibodies were used: phospho-ERK (p-ERK1/2; Thr202/Tyr204), ERK1/2, phospho-Akt (p-AKT; Ser473), phosphorylated mammalian target of rapamycin (p-mTOR; Ser2448), mTOR, p-S6 (Ser235/236), S6 (all from Cell Signaling Technology), mGluR5 (Abcam), mGluR1 (BD Biosciences), and β-actin (Abcam). Bands were detected by chemiluminescence (ECL; GE Healthcare) or IR fluorescence (LI-COR). Quantifications were done with Quantity-One (Bio-Rad). The relative expression levels of each protein were determined by the intensity of target immunoblot bands normalized to the total protein level of each lane (MemCode intensity). A paired two-tailed t-test was used to determine whether differences between genotypes were statistically significant at p < 0.05.

Metabolic labeling. Protein synthesis measurements were done as described previously with paired WT and Mecp2 KO littermates (Osterweil et al., 2010). Briefly, 500 μM hippocampal slices were prepared with a Stooling tissue slicer and recovered for 3 h at 32.5°C ACSF, incubated for 30 min with 25 μM actinomycin D (EMD Biosciences), and then transferred to ACSF with 10 μCi/ml 35SMet/Cys (PerkinElmer) for 30 min. Labeled slices were homogenized in protein lysis buffer (10 mM HEPES, pH 7.4, 2 mM EDTA, 2 mM EGTA, 1% TX100, and protease inhibitor; Roche) and unincorporated amino acids were removed by precipitating proteins in the homogenate with trichloroacetic acid. Isotope incorporation was measured with a scintillation counter (Beckman). Protein concentration was measured by
DC Protein assay (Bio-Rad). Protein synthesis rate was calculated as counts per minute per microgram of protein and the reading was normalized to the ACSF 35SMet/Cys counts. A paired two-tailed t test was used to determine whether differences between genotypes were statistically significant at p < 0.05.

TRAP-seq and differential gene expression analysis. Translating mRNAs were immunoprecipitated from acutely dissected hippocampal tissue and purified as described previously (Heiman et al., 2008; Heiman et al., 2014). RNA samples were analyzed by a Bioanalyzer (Agilent) to confirm RNA integrity (RIN > 7). RNA concentrations were determined with the Quant-it Ribogreen RNA assay (Life Technologies). Purified RNA (1–1.5 ng) was converted to cDNAs with Ovation RNA-seq V2 system (NuGEN). A total of 500 ng of cDNAs from each sample were fragmented to ~200 bp using a Covaris S2 ultrasonicator. Fragmented cDNA (100 ng) was end-repaired, A-tailed, and ligated to adaptors using the NEBNext Ultra DNA library prep kit (New England Biolabs). Sequencing libraries were prepared using the KAPA HiFi Hotstart Ready Mix PCR Kit (Kapa Biosystems) and NEBNext Multiplex Oligos for Illumina (Index Primers Set1 and 2). Library quality was examined with the Qubit dsDNA HS Assay Kit (Life Technologies) and Bioanalyzer using a High Sensitivity DNA kit (Agilent). Final concentrations of sequencing libraries were quantified by qPCR using KAPA Library Quantification Kit (Kapa Biosystems). TRAP-seq libraries were sequenced on a HiSeq 2500 or a NextSeq 500 Sequencer (Illumina). Sequencing reads (50 bp, single-end) were first mapped to the Mus musculus primary assembly reference genome (Genode GRCh38/release M6) using STAR 2.4.2a. Uniquely mapped reads that overlapped with exons of known protein coding genes were counted using htsq-seq-count python script. Differential expression was calculated using DESeq2 (Love et al., 2014) and p-values were adjusted for multiple testing using the Benjamini–Hochberg procedure (Gene accession number: GSE82068).

Gene set enrichment analysis (GSEA). GSEA analysis was performed as described previously (Subramanian et al., 2005) using a modified GSEA 1.0 R script (implemented in R-3.1.3). Normalized enrichment score and statistical significance were estimated by comparison with a null model generated by permuting the gene labels randomly 1000 times. FMRP direct targets used in GSEA analysis were downloaded from the FMRP HTS-CLIP dataset (Darnell et al., 2011).

Gene ontology (GO) analysis. GO analysis (see Fig. 3d) was performed using the DAVID version 6.7 bioinformatics resource (http://david.abcc.ncifcrf.gov/).

Protein–protein network analyses. Protein–protein interaction (PPI) network analysis was performed using the GeNet program (https://www.broadinstitute.org/genets) and the InWeb PPI database. A set of genes (nodes in the network) was grouped as a PPI community if they were more connected to one another than they were to other groups of genes. Created and computationally derived PPIs were shown as lines. Each PPI interaction was assigned a credibility score between 0 and 1, where 1 are “gold standard interactions,” indicated by thick black lines. The scores other than 1 were defined based on the number of citations and types of experiments that lend evidence toward the interaction. The connectivity p-value indicates whether the observed PPI network is significantly more connected than expected for a random gene set of same size. GSEA was performed using a Bonferroni-adjusted hypergeometric test and only the C2 set (4722 curated gene sets from BioCarta, KEGG, Reactome, PID, etc.) from the Molecular Signatures Database (MSigDB) was considered during this analysis. SFARI genes were downloaded from the SFARI human gene collection (https://gene.sfari.org/autdb/Welcome.do).

CTEP treatment. Chronic CTEP treatment (0.4 mg/kg) was administered via subcutaneous injection (for mice younger than P30) or oral gavage (for mice older than P30) once every 48 h. This dose was chosen after a pilot study revealed that the dose of 2 mg/kg used in previous studies in fragile X (Michalon et al., 2012) and 16p11.2 microdeletion (Tian et al., 2015) mouse models caused significant weight loss in the Mesp2 mice.

Body plethysmography. Breathing was recorded in awake and unrestrained mice using whole-body plethysmography (EMKA Technologies) with a constant inflow of fresh air (0.8 L/min). Mice were habituated to the chamber for 20 min 1 d before being recording for up to 1.5 h. Raw data were reported and analyzed in Matlab (The MathWorks).

Immunohistochemistry and soma size analyses. Mice were perfused with PBS, followed by 4% paraformaldehyde (PFA), and brains were sliced into 50-μm-thick sections in PBS with a vibratome (Leica). Brain sections were blocked and permeabilized for 1 h at room temperature in a blocking buffer of 1×PBS with 5% normal donkey serum and 0.16% Triton X-100. For immunostaining, sections were incubated with primary antibody overnight, washed 3 times with PBS, incubated with secondary antibody for 1.5 h, washed 3 times with PBS, and then mounted onto slides and coverslipped. The following antibodies were used for immunostaining: GEP (Abcam, rabbit polyclonal, 1/1500), NeuN (EMD Millipore, mouse monoclonal, 1/500). For Nissl staining, permeibilized brain sections were incubated with Neurotrace (Life Sciences, 1/100) for 30 min at room temperature, washed 3 times with PBS, and then mounted onto slides and coverslipped. Images were taken with a confocal microscope. Only neurons with clear nuclei were quantified and soma sizes were analyzed with Fiji (ImageJ) software by an experimenter blinded to genotype and treatment. Two sample Kolmogorov–Smirnov (KS) tests were used to determine whether the differences between each genotype/treatment (based on cell number) were statistically significant. Two-way ANOVA was used to determine whether the differences between genotype/treatment were statistically significant.

Inhibitory avoidance test. Inhibitory avoidance test was performed as described previously (Dölen et al., 2007, Michalon et al., 2012). Mice were placed in the lit compartment of a two-chamber box for 90 s before the shutter separating the two compartments opened. At 0 h training time, once the animal entered the dark compartment, it received a single foot shock of 0.5 mA for 2 s. Mice then stayed in the dark compartment for 120 s before being returned to their home cages. Mice were placed back in the lit chamber at 24 and 48 h after conditioning to measure the latency to enter the dark compartment. They were exposed to the dark compartment for 120 s without receiving any additional foot shock at 24 and 48 h time points. Two-way repeated-measures (RM) ANOVA was used to determine whether the differences between genotype/treatment or genotype and treatment effects were statistically significant.

Contextual fear conditioning. Mice were fear conditioned to the training context with a single foot shock of 0.8 mA for 2 s as described previously (Auerbach et al., 2011). They were returned 24 h later either to the same context or to a novel context (varying distal cues, odor, lighting, and floor material). Conditioned fear response was assessed by measuring the percentage of time spent freezing during a test period of 3 min. Two-way ANOVA was used to determine whether the differences between genotype/treatment were statistically significant.

Elevated plus maze. The elevated plus maze consisted of two open arms and two closed arms with an elevation of 30 cm from the ground. Each arm was 10 cm × 40 cm. Mice were placed in the center of an elevated plus maze facing an open arm and videotaped for 15 min. The total time spent on the open arms versus the close arms were recorded and calculated. Two-way ANOVA was used to determine whether the differences between genotype/treatment were statistically significant.

Marble-burying test. The marble-burying test was performed as described previously (Deacon, 2006). Mice were placed and left for 30 min in a cage with ~5 cm deep of bedding and 2 rows of marbles with regular spacing in between. The marbles that were buried (to 2/3 of their depth) were displaced from their original positions were counted. Two-way ANOVA was used to determine whether the differences between genotype/treatment were statistically significant.
Calfa et al., 2011

Results

We first measured chemically induced mGluR-LTD at Schaffer collateral–CA1 synapses using hippocampal slices from P30–P35 mice as described previously (Huber et al., 2001). At this age, Mecp2 KO mice in our colony exhibited no hindlimb clasping, few tremor and mobility problems, and were considered to be “early symptomatic.” mGluR-LTD can be induced by brief application of the selective mGluR1/5 agonist DHPG or by repetitively stimulating Schaffer collateral axons using paired pulses (50 ms interval) at 1 Hz (PP-LFS). A previous study using a loss-of-function RTT model (Mecp2(+/−) mice) showed that DHPG-LTD magnitude was not altered, whereas PP-LFS-LTD was impaired (Moretti et al., 2006). The discrepancy is likely due to the fact that the PP-LFS protocol is dependent on presynaptic glutamate release to induce LTD and both Mecp2(+/−) mice and Mecp2 KO mice have presynaptic neurotransmission abnormalities (Moretti et al., 2006; Calfa et al., 2011; J.T. and M.F.B., unpublished observations). Because our interest was in postsynaptic regulation of protein synthesis, we reexamined the effects of DHPG in the presence and absence of cycloheximide (CHX), an mRNA translation inhibitor. We confirmed the finding that application of DHPG induces a similar magnitude of LTD in both WT and Mecp2 KO littermates (WT: 9.8%, KO: 11.3%).

Figure 1. Mecp2 KO mice exhibited dysregulated protein-synthesis-dependent mGluR-LTD in hippocampus. a, DHPG (50 μM, 5 min) induced comparable magnitudes of mGluR-LTD in hippocampal slices of P30–P35 littermate WT (22.1 ± 1.6%, n = 10 mice) and Mecp2 KO (22.7 ± 1.4%, n = 11). b, The protein synthesis inhibitor CHX significantly reduced mGluR-LTD in WT (11.0 ± 4%, n = 10 mice), but did not alter mGluR-LTD in Mecp2 KO (20.9 ± 1.6%, n = 11). Statistics: 2-way ANOVA, interaction p = 0.031, genotype p = 0.021, treatment p = 0.006. Tukey’s multiple-comparisons test WT vs WT + CHX ***, KO vs KO + CHX ns (in this and subsequent figures, *p < 0.05; **p < 0.01; ***p < 0.001). c, Metabolic labeling of P30–P35 hippocampal slices revealed a significant increase in basal protein synthesis in Mecp2 KO mice (KO: 113 ± 10%, n = 22 mice) compared with WT littermate (WT: 100 ± 8.4%, n = 22) (paired t test, p = 0.03). d, ERK1/2 phosphorylation were comparable between P30–P35 WT and Mecp2 KO hippocampal slices stimulated with DHPG (50 μM, 5 min) (WT: 100 ± 4.6%, WT + DHPG: 122 ± 3.9%, KO: 95.7 ± 4.9%, KO + DHPG: 123.5 ± 4.2%, n = 17 animals for both WT and KO) (2-way ANOVA, treatment p < 0.0001, interaction and genotype n.s., Sidak’s multiple-comparisons test WT vs WT + DHPG, p < 0.0001, KO vs KO + DHPG, p < 0.0005). e, AKT phosphorylation was comparable between P30–P35 WT and Mecp2 KO hippocampal slices stimulated with insulin (1 μM, 10 min) (WT: 100 ± 9.6%, WT + insulin: 200 ± 21%, KO: 108 ± 11.7%, KO + insulin: 209 ± 17.6%, n = 4 animals for both WT and KO) (2-way ANOVA, treatment p < 0.0005, interaction and genotype n.s., Sidak’s multiple-comparisons test WT versus WT + DHPG, p < 0.05, KO vs KO + DHPG, p < 0.05). f, Normalized ratio of mGluR5 expression level to total protein amount between P30–P35 WT and KO littermates was not significantly altered (WT: 1 ± 3.7%, n = 9; KO: 95 ± 4.0%, n = 9, 2-tailed paired t test p = 0.459). g, Normalized ratio of mGluR1 expression level to total protein amount between P30–P35 WT and KO littermates was not significantly altered (WT: 100 ± 9.8%, n = 9; KO: 115.6 ± 15.6%, n = 9, 2-tailed paired t test p = 0.328).

Figure 1. mGluR-LTD in hippocampus. a, DHPG (50 μM, 5 min) induced comparable magnitudes of mGluR-LTD in hippocampal slices of P30–P35 littermate WT (22.1 ± 1.6%, n = 10 mice) and Mecp2 KO (22.7 ± 1.4%, n = 11). b, The protein synthesis inhibitor CHX significantly reduced mGluR-LTD in WT (11.0 ± 4%, n = 10 mice), but did not alter mGluR-LTD in Mecp2 KO (20.9 ± 1.6%, n = 11). Statistics: 2-way ANOVA, interaction p = 0.031, genotype p = 0.021, treatment p = 0.006. Tukey’s multiple-comparisons test WT vs WT + CHX ***, KO vs KO + CHX ns (in this and subsequent figures, *p < 0.05; **p < 0.01; ***p < 0.001). c, Metabolic labeling of P30–P35 hippocampal slices revealed a significant increase in basal protein synthesis in Mecp2 KO mice (KO: 113 ± 10%, n = 22 mice) compared with WT littermate (WT: 100 ± 8.4%, n = 22) (paired t test, p = 0.03). d, ERK1/2 phosphorylation were comparable between P30–P35 WT and Mecp2 KO hippocampal slices stimulated with DHPG (50 μM, 5 min) (WT: 100 ± 4.6%, WT + DHPG: 122 ± 3.9%, KO: 95.7 ± 4.9%, KO + DHPG: 123.5 ± 4.2%, n = 17 animals for both WT and KO) (2-way ANOVA, treatment p < 0.0001, interaction and genotype n.s., Sidak’s multiple-comparisons test WT vs WT + DHPG, p < 0.0001, KO vs KO + DHPG, p < 0.0005). e, AKT phosphorylation was comparable between P30–P35 WT and Mecp2 KO hippocampal slices stimulated with insulin (1 μM, 10 min) (WT: 100 ± 9.6%, WT + insulin: 200 ± 21%, KO: 108 ± 11.7%, KO + insulin: 209 ± 17.6%, n = 4 animals for both WT and KO) (2-way ANOVA, treatment p < 0.0005, interaction and genotype n.s., Sidak’s multiple-comparisons test WT versus WT + DHPG, p < 0.05, KO vs KO + DHPG, p < 0.05). f, Normalized ratio of mGluR5 expression level to total protein amount between P30–P35 WT and KO littermates was not significantly altered (WT: 1 ± 3.7%, n = 9; KO: 95 ± 4.0%, n = 9, 2-tailed paired t test p = 0.459). g, Normalized ratio of mGluR1 expression level to total protein amount between P30–P35 WT and KO littermates was not significantly altered (WT: 100 ± 9.8%, n = 9; KO: 115.6 ± 15.6%, n = 9, 2-tailed paired t test p = 0.328).
mice showed a small but significant increase in 35S-methionine/cysteine incorporation indicative of enhanced basal protein translation (Fig. 1c). However, we observed no difference in basal or evoked levels of p-ERK (stimulated by DHPG), and p-AKT (stimulated by insulin) in the mutant slices compared with those from WT littermates (Fig. 1d,e), and no differences in mGluR5 or mGluR1 in hippocampal tissue lysates (Fig. 1f,g). Collectively, these results indicate that the mGluR-ERK and AKT signaling pathways are unaffected in early symptomatic stage Mecp2 KO hippocampal slices and may not contribute to the elevated basal protein synthesis. However, we cannot exclude the possibility that signaling pathways may be altered in a cell-type-specific manner. Western blotting with hippocampal slices provides limited information toward that end.

Bulk protein synthesis measurements and candidate protein expression analysis (e.g., Western blotting of individual proteins) from whole hippocampus slices lack cell-type specificity and cannot determine the identities of dysregulated mRNAs without prior knowledge. Because the pyramidal neurons in CA1 are those displaying the mGluR-LTD phenotype, it is highly desirable to identify translational dysregulation specifically in these neurons in an unbiased manner. To this end, we used translating ribosome affinity purification followed by RNA-sequencing (TRAP-seq) to investigate the translatome in hippocampal CA1 neurons. Compared with standard RNA-seq analysis of specific cell populations isolated by fluorescence-activated cell sorting or laser dissection, TRAP-seq provides the unique advantage of cell-type specific profiling of mRNAs from intact undisturbed brain tissues (Doyle et al., 2008, Heiman et al., 2008, Sanz et al., 2009) and measures the levels of mRNAs that are associated with ribosomes. To analyze hippocampal CA1 neurons, we used a BAC transgenic mouse line with EGFP-L10a expression driven by a cholecystokinin (Cck) promoter. Cck is a neuropeptide that in hippocampus is widely expressed by pyramidal neurons in fields CA1–3 and by a specific class of inhibitory interneuron. However, in the Cck-bacTRAP line, hippocampal expression

**Figure 2.** Characterization of Cck-bacTRAP line and immunoprecipitation of ribosome associated mRNAs from hippocampal CA1 neurons. a, Coronal section of a Cck-bacTRAP mouse brain stained for GFP and Nissl. Inset picture is an immunohistochemistry image of hippocampus with antibodies against GFP (cyan) and NeuN (magenta) showing colocalization in CA1. Scale bar, 100 μm. b, Volcano plot analysis revealed transcripts specifically enriched in Cck-bacTRAP IP samples versus input samples (whole hippocampus lysates). Red dots represent transcripts that were significantly enriched in IP samples (e.g., Cck) and blue dots represent transcripts that were significantly enriched in input samples (e.g., Gfap, Gad2). c, Quantification of expression levels of Slc17a7 (Vglut1, excitatory neuron marker), Gad1 (inhibitory neuron marker), and Aldh1l1 (glial marker) across different bacTRAP lines expressing in different cell types: Cck (hippocampal CA1, from current study), Nd1 (cerebellar granule neuron), Sept4 (cerebellar Bergmann glia), Pcp2 (cerebellar Purkinje cell); the latter three are all published datasets from Dr. Heintz’s group (Mellén et al., 2012). FPKM, Fragments per kilobase of transcript per million mapped reads.
**Figure 3.** Analysis of MeCP2-regulated ribosome-associated mRNAs in hippocampal CA1 neurons. 

**a,** MA plot (DESeq2) showing log2-fold changes between MeCP2 KO/WT over the mean of normalized transcript counts. TRAP-seq analyzed translating mRNAs isolated from hippocampal CA1 neurons in WT Cck bacTRAP mice (n = 4) and MeCP2 KO Cck-bacTRAP mice (n = 4). Red dots represent transcripts that were significantly upregulated in MeCP2 KO (n = 197, false discovery rate [FDR] = 0.1) and blue dots represent transcripts that were significantly downregulated in MeCP2 KO (n = 66, FDR = 0.1). Gray dots represent transcripts not significantly altered. The data point corresponding to the MeCP2 mRNA is indicated. 

**b,** Heat map of transcripts that are significantly differentially expressed between WT and MeCP2 KO. Each column represents one biological replicate (animal) (FDR = 0.1) with age marked at the bottom. 

**c,** Cumulative distribution of gene lengths for genes upregulated in MeCP2 KO (red), genes downregulated in MeCP2 KO (blue), and all the unaltered genes detected in hippocampal CA1 neurons (gray). Two-sample KS test: upregulated versus no change, p = 4.6 × 10^{−9}; downregulated versus no change, p = 0.21. 

**d,** Functional annotation analysis of genes upregulated in MeCP2 KO using DAVID Bioinformatics Resources 6.7 (National Institute of Allergy and Infectious Diseases–National Institutes of Health). The top 20 enriched GO terms with p < 0.05 (corrected for multiple comparisons by Benjamin adjustment) are shown with expected (gray bars) and observed (red bars) percentages of genome. 

**e,** PPI network analysis of 197 genes upregulated in MeCP2 KO generated by the GeNets algorithm using the InWeb PPI database (https://www.broadinstitute.org/genets). Curated and computationally derived PPIs are shown as lines. Line thickness reflects the level of confidence in the interaction. Sets of genes more connected with each other than to other groups of genes are defined as PPI communities and are enclosed by the ovals bounded by dashed lines. (Figure legend continues.)
ase, enriched in Purkinje cells) and aberrantly upregulated genes (Fig. 4). We further compared our results with the Cck-bacTRAP line with published datasets from TRAP lines that specifically label cerebellar granule neurons (Nd1), Bergmann glia (Sep4), and Purkinje neuron (Pcp2) (Mellén et al., 2012). Immunoprecipitated mRNAs from the Cck line expressed high levels of Slc17a7 (vesicular glutamate transporter, expressed only in glutamatergic neurons), but very low levels of Gad1 (glutamic acid decarboxylase, enriched in Purkinje cells) and Aldh111 (aldehyde dehydrogenase, a glial marker) (Fig. 2c). The robust enrichment of glutamatergic neuronal markers compared with non-neuronal and inhibitory neuronal markers demonstrates that the Cck-bacTRAP line is suitable to study translating mRNA dysregulation in hippocampal CA1 excitatory neurons.

Next, we crossed the Mecp2<sup>−/−</sup> line with the Cck-bacTRAP line to obtain Mecp2<sup>−/−</sup>;Cck (WT) and Mecp2<sup>−/−</sup>;Cck (KO) littermates. Mecp2<sup>−/−</sup>;Cck mice exhibited the same behavioral phenotypes and premature death as Mecp2<sup>−/−</sup> mice. We profiled ribosome-bound mRNAs from four pairs of littermates (from P37–P60) and identified transcripts that showed consistent significant differential expression between Mecp2 KO mice and their littermate WT controls (Fig. 3a,b). Loss of MeCP2 caused dysregulation of a cohort of mRNAs (n = 263, false discovery rate < 0.1) across multiple biological replicates (Fig. 3b). The majority of the dysregulated transcripts were increased in the Mecp2 KO (197 genes, 74.9%); the remaining transcripts were downregulated (66 genes, 25.1%). This result indicates that, in hippocampal CA1 neurons, MeCP2 acts predominantly as a repressor of gene expression and suggests that the previously observed increased bulk protein synthesis might be explained by increased levels of mRNAs associated with translating ribosomes. Interestingly, aberrantly upregulated genes (n = 197, p = 4.6 × 10<sup>−34</sup>, KS test), but not downregulated genes (n = 66, p = 0.21, KS test), were significantly longer compared with unaltered genes detected in hippocampal CA1 neurons (Fig. 3c). Therefore, our hippocampal CA1 specific profiling data support the recent observations that MeCP2 represses long genes preferentially in hippocampal CA1 specific profiling data support the recent observations that MeCP2 represses long genes preferentially in hippocampal CA1 neurons (Sugino et al., 2014, Gabel et al., 2015). GO analysis of genes upregulated in the KO (n = 197) indicates that they are significantly enriched for GO terms related to cytoskeleton organization and cellular/neuronal projection morphogenesis (Fig. 3d), which is consistent with previous GO analysis with commonly upregulated genes from multiple published microarray and RNA-sequencing datasets from various brain regions (Gabel et al., 2015). In contrast, GO analysis of genes downregulated in the KO (n = 66) did not reveal any significant biological processes or pathways. To visualize the known interactions among proteins encoded by upregulated genes, the data were analyzed using the GeNets algorithm (Fig. 3e). This analysis revealed clustering of affected genes into six distinct PPI communities, suggesting that some aberrantly upregulated genes in Mecp2 KO mice may participate in the assembly of macromolecular complexes that contribute synergistically to Rett pathology. Further comparison of the PPI network of MeCP2-repressed genes with the SFARI human autism gene database indicated that 32 of 197 genes upregulated in the KO have been identified as genes mutated in ASD patients (Fisher’s exact test, p = 2.38 × 10<sup>−3</sup>, see Fig. 3e). Therefore, many MeCP2-repressed genes identified in area CA1 by TRAP-seq are independently implicated as risk alleles in ASDS.

Recent studies suggest that the RNA-binding protein FMRP preferentially stalls ribosomes on translating mRNAs of long length (Darnell et al., 2011, Gabel et al., 2015). We compared the genes upregulated in the Mecp2 KO (197 genes) with FMRP-bound mRNA targets (735 expressed in hippocampal CA1 neurons of the original 842 genes) and observed a significant overlap of 49 genes (24.9% of MeCP2 repressed genes, p = 1.1 × 10<sup>−2</sup>, Fisher’s exact test; Fig. 4a; representative validations by qPCR in Fig. 4b). In contrast, only 7 genes downregulated in the KO are also FMRP targets (10.6%, p = 0.033; Fig. 4a). The significant overlap between genes upregulated in the Mecp2 KO and FMRP direct targets raises the possibility that MeCP2 and FMRP might regulate a common group of mRNAs at the transcriptional and translational levels, respectively. Among the 49 genes that are FMRP direct targets and upregulated in Mecp2 KO, 14 genes have been identified as ASD risk genes in the SFARI human autism gene database (Fisher’s exact test, p = 3.14 × 10<sup>−3</sup>). Interestingly, whereas the FMRP-bound genes reported by Darnell et al. (2011) were significantly longer than non-FMRP target genes, the 49 MeCP2-repressed/FMRP-bound genes were even longer still (Fig. 4c).

Studies of the Fmr1<sup>−/−</sup> mouse have shown that the increased protein synthesis caused by loss of FMRP in the hippocampus is downstream of a signaling pathway recruited by activation of mGluR5 (Ostrowski et al., 2010, Bhakar et al., 2012). Chronic inhibition of mGluR5 with a negative allosteric modulator can correct a wide array of disease phenotypes in Fmr1 KO mice (Michalon et al., 2012). Because a significant portion of genes upregulated in Mecp2 KO are FMRP targets, we wondered whether they also might be subjected to regulation by the mGluR5 signaling pathway. We therefore treated Mecp2 KO mice with either vehicle or an mGluR5-negative allosteric modulator (NAM), 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethyl)pyridine (CTEP) from P30 to P60 and investigated the molecular changes in Mecp2 KO (n = 3 animals for KO treated with CTEP, n = 2 animals for KO treated with vehicle) hippocampal CA1 neurons by TRAP-seq. Using GSEA (Mootha et al., 2003, Subramanian et al., 2005), we ranked genes according to their differential expression between vehicle- versus CTEP-treated conditions. Interestingly, both the 49 shared MeCP2-repressed/FMRP targets and the total set of 197 genes upregulated in the Mecp2 KO showed a significant shift toward the left side (vehicle-treated) of the ranked gene list, indicating that CTEP treatment tends to reduce their expression levels in Mecp2 KO. In contrast, the 66 genes downregulated in Mecp2 KO as a gene set showed a random distribution (Fig. 4d). These analyses indicate that MeCP2-repressed genes, particularly those genes regulated by both MeCP2 and FMRP, might be specifically subject to regulation by CTEP treatment.

PPI analysis of the genes that responded most to CTEP treatment (108 leading edge genes, which are those on the left side of
Figure 4. Genes upregulated in Mecp2 KO have a significant overlap with FMRP direct mRNA targets. The list of FMRP directly associated mRNAs from the mouse brain tissue is from published datasets (Darnell et al., 2011). a, Venn diagrams showing a significant overlap between FMRP direct mRNA targets and mRNAs upregulated in Mecp2 KO (Fisher’s exact test, $p = 1.1 \times 10^{-22}$) and a fewer number of genes overlapping between FMRP direct targets and mRNAs downregulated in Mecp2 KO (Fisher’s exact test, $p = 0.033$). b, Validation of TRAP-seq identified target genes that were shared between genes upregulated in Mecp2 KO and FMRP direct mRNA targets by qPCR. Two-tailed paired t tests: Herc2 $p = 0.0099$ **, Ank2 $p = 0.0296$ *, Myh10 $p = 0.0335$ *, Apoe $p = 0.0117$ *, Myo18a $p = 0.02$ *, Dyn1h1 $p = 0.0039$ **, $n = 4$ animals. c, Cumulative distribution of gene lengths for FMRP targets upregulated in Mecp2 KO (cyan), other FMRP direct targets (magenta), and the rest of mRNAs that are non-FMRP targets (gray). Two-sample KS test: FMRP targets upregulated in Mecp2 KO versus non-FMRP targets $p = 1.2 \times 10^{-37}$, d, GSEA of genes upregulated in Mecp2 KO (red vertical bars, $n = 197$), upregulated in Mecp2 KO/FMRP-bound mRNAs (cyan vertical bars, $n = 49$), or genes downregulated in Mecp2 KO (blue vertical bars, $n = 49$) on a ranked list of genes differentially expressed between vehicle-treated and CTEP-treated Mecp2 KO hippocampal CA1 neurons. Genes that are relatively downregulated in CTEP-treated Mecp2 KO are displayed on the left side of the plot. The red and cyan line in the upper part of the plot indicates the GSEA enrichment running scores for the list of genes upregulated or downregulated in Mecp2 KO, respectively. The vertical dash lines indicate the peaks corresponding to enrichment score (ES). e, PPI network analysis of a subset of genes upregulated in Mecp2 KO that are downregulated by the CTEP treatment ($n = 197$ leading edge genes). This analysis identified five distinct PPI communities. In addition, genes that are identified as SFARI ASD genes are highlighted as larger nodes, whereas those overlapping with FMRP-bound targets are highlighted in red. Genes significantly enriched in two functionally relevant pathways are labeled with green outer-circle (NCAM signaling for neurite out growth, adjusted $p = 5.8 \times 10^{-7}$) or blue outer-circle (Calcium signaling pathway, adjusted $p = 1.7 \times 10^{-7}$), respectively. Gene names are indicated for those that are enriched in the two pathways.
the peak of enrichment score, indicated by red dashed vertical lines in Fig. 4d) identified five distinct PPI communities, of which community 1 is enriched for actin binding, calmodulin binding, and cytoskeleton binding genes and community 2 is enriched for actin cytoskeleton organization (DAVID GO analysis of biological processes). Additional pathway enrichment analysis (using the Reactome and KEGG pathway database) indicated that these genes were enriched in two pathways: calcium signaling and NCAM signaling for neurite out growth (Fig. 4e). For example, Ryr2 and Iptr2 are both involved in internal calcium release regulation upon mGlur activation. Downregulation of both with CTEP treatment may therefore tune down aberrant calcium signaling. Together, these results suggest that CTEP may have potential to ameliorate Mecp2 KO symptoms phenotypically by modulating the expression of a subset of MeCP2-repressed genes.

We next investigated the effect of chronic CTEP treatment on a battery of RTT phenotypes. One of the neurostructural hallmarks of RTT mice highly relevant to cellular health is reduced neuronal soma size, which had been reproducibly observed across multiple loss-of-function Mecp2 mutant mouse lines and cellular RTT models (Taneja et al., 2009, Goffin et al., 2012, Yazdani et al., 2012, Li et al., 2013, Wang et al., 2013). Consistent with the observation that many cytoskeleton genes were aberrantly upregulated in Mecp2 KO and tuned down by CTEP treatment, we found that chronic treatment with CTEP significantly ameliorated the CA1 soma size deficit observed in Mecp2 KO mice at P45–P60 (Fig. 5a,b). This effect appears to constitute a “rescue” of the mutant phenotype because treatment was without any significant effect in the WT.

Chronic treatment with low-dose CTEP starting at P30 also prolonged the lifespan of RTT mice significantly (Fig. 5c). Mecp2 KO mice have severe cardiorespiratory deficits, with irreplaceable patterns and breath holding, recapitulating human patients symptoms and likely contributing to premature mortality (Katz et al., 2009, Tarquinio et al., 2015). Therefore, we evaluated the breathing patterns of awake, freely moving mice at a symptomatic age (~P45–P60) with whole-body plethysmography. Analysis of the interbreath intervals revealed that CTEP treatment partially reduced long breathholdings in the Mecp2 KO (>1 s) compared with vehicle-treated KO mice.

**Figure 5.** Chronic CTEP treatments of Mecp2 KO mice ameliorates hippocampal reduced soma size, prolongs lifespan, partially reduces long breathholdings, and ameliorates IA deficits. a, CTEP treatment ameliorates reduced neuronal soma size shown by averaged soma size by animals (WT_vehicle 100.17 ± 1.32 μm²; WT_CTEP 101.51 ± 1.48 μm² = 4, KO_vehicle 91.59 ± 2.3 μm²; KO_CTEP 99.11 ± 1.09 μm², 7, KO_CTEP 99.11 ± 1.09 μm²; 7, 2-way ANOVA, interaction p = 0.056, genotype p = 0.012, genotype × treatment p = 0.008, Sidak’s multiple-comparisons test WT_vehicle vs WT_CTEP n.s., KO_vehicle vs KO_CTEP **). b, CTEP treatment ameliorates reduced neuronal soma size in hippocampal CA1 neurons shown in cumulative distribution by cell numbers (KS test: WT_vehicle vs WT_CTEP n.s., KO_vehicle vs KO_CTEP n.s., KO_CTEP vs WT_vehicle p = 0.044, Kaplan–Meier survival curve showed that Mecp2 KO mice with treated CTEP survived longer than littermates treated with vehicle (KO_vehicle: 0 h 28.59 median survival is 83 d, KO_CTEP: n = 11 median survival is 113 d. Log-rank test, p = 0.038). d, Whole-body plethysmography analyses showed that CTEP treatment may partially reduce long breathholdings (>1 s) in Mecp2 KO mice (WT_vehicle 0.355 ± 0.118, n = 8; WT_CTEP 0.244 ± 0.056, n = 7; KO_vehicle 1.159 ± 0.218, n = 11; KO_CTEP 0.663 ± 0.129, n = 11; 2-way ANOVA, interaction p = 0.251, treatment p = 0.0748, genotype p = 0.0008, Tukey’s multiple-comparisons test WT_vehicle vs KO_vehicle ***, KO_vehicle vs WT_CTEP ***, WT_CTEP vs WT_CTEP n.s., KO_vehicle vs KO_CTEP vs WT_CTEP n.s., WT_CTEP vs KO_CTEP n.s., WT_vehicle vs KO_CTEP n.s., KO_vehicle vs KO_CTEP n.s., e, CTEP treatment ameliorated IA deficits in Mecp2 KO mice. CTEP treatment did not alter acquisition of IA in WT mice (WT_vehicle: 0 h 37.26 ± 8.26 n = 8, 24 h 217.36 ± 36.32 n = 8; 48 h 237.95 ± 71.17; WT_CTEP: 0 h 46.45 ± 7.92, 24 h 288.46 ± 47.71, 48 h 193.61 ± 46.36, n = 13, 2-way RM-ANOVA, interaction p = 0.286, treatment p = 0.794, time p < 0.0001; Sidak’s multiple-comparisons tests: 0 h vs 24 h **, 0 h vs 48 h **, 24 h vs 48 h n.s., WT_vehicle n = 8; 0 h vs 24 h **, 0 h vs 48 h **, 24 h vs 48 h n.s., 48 h vs 48 h n.s., WT_CTEP n = 13). CTEP treatment ameliorated acquisition deficits in Mecp2 KO mice (KO_vehicle: 0 h 28.39 ± 7.04, 24 h 86.6 ± 20.6, 48 h 52.21 ± 20.00 n = 8; KO_CTEP: 0 h 49.16 ± 10.73, 24 h 130.22 ± 16.80, 48 h 121.29 ± 28.81, n = 11; 2-way RM-ANOVA, interaction p = 0.383, treatment p = 0.036, time p = 0.001; Sidak’s multiple-comparisons test: KO_vehicle n = 8, 0 h vs 48 h n.s., 0 h vs 48 h n.s., 24 h vs 48 h n.s.; KO_CTEP n = 11, 0 h vs 24 h **, 0 h vs 48 h **, 24 h vs 48 h n.s.; KO_vehicle vs KO_CTEP 48 h **).
Figure 6. CTEP treatment of Mecp2 KO mice does not improve body weight, tremor, hindlimb clasping, mobility, or anxiety deficits. a, CTEP treatment does not improve body weight, tremor, hindlimb clasping, or mobility on an open bench (severity score: 0 equals WT, 1 is partially impaired, 2 is severely impaired). C, Open-field test showing that Mecp2 KO mice traveled less than WT littermates in a 20 min window regardless of vehicle or CTEP treatment (2-way ANOVA, genotype \( p = 0.0025 \), treatment and interaction ns, WT_V \( n = 7 \), WT_CTEP \( n = 7 \), KO_V \( n = 11 \), KO_CTEP \( n = 10 \)). The same open-field test also showed that Mecp2 KO mice spent less time in the center versus margin of the test arena compared with WT littermates regardless of vehicle or CTEP treatment (2-way ANOVA, genotype \( p = 0.0006 \), treatment and interaction not significant, WT_V \( n = 5 \), WT_CTEP \( n = 5 \), KO_V \( n = 7 \), KO_CTEP \( n = 8 \)). d, Open-field test on the first day divided into bins of 5 min showed that, whereas WT littermate ran the most distance during the first 5 min and then gradually reduced exploration, Mecp2 KO mice did not reach peak exploration until 10 min later (2-way RM-ANOVA, WT_V vs KO_V: interaction \( p = 0.0004 \), time \( p < 0.0001 \), genotype \( p = 0.103 \); KO_V vs KO_CTEP: interaction \( p = 0.0501 \), time \( p = 0.0003 \), treatment \( p = 0.8244 \)). Open-field test on 2 consecutive days showed that both WT and KO mice regardless of drug treatment habituated to the environment (2-way RM-ANOVA, WT_V vs KO_V: interaction \( p = 0.776 \), time \( p = 0.003 \), genotype \( p = 0.22 \); KO_V vs KO_D: interaction \( p = 0.737 \), time \( p = 0.0003 \), treatment \( p = 0.477 \)). e, Regardless of CTEP treatment, compared with WT, Mecp2 KO mice spent more time in the open arm than in the closed arm in the elevated plus maze (WT_vehicle_open arm: 0.033 ± 0.013 \( n = 5 \); WT_CTEP_open arm: 0.121 ± 0.027 \( n = 7 \)). (Figure legend continues.)
the same context condition: 2-way ANOVA, interaction

- 

behavior in either the same or different context (KO_vehicle_same context: 3.48

/H11005

n

WT_vehicle_same context: 28.26

/H11006

5; KO_CTEP_same context: 7.29

/H11006

/0.056

p

Comparison of WT and KO in

/0.0001.

Discussion

Dysregulated hippocampal mGluR-LTD and protein synthesis

have been demonstrated in several mouse lines carrying gene

mutations that cause human ASD and ID, including the models

for FXS, TSC, and 16p11.2 microdeletion (Huber et al., 2002,

Auerbach et al., 2011, Tian et al., 2015). In the current study,

demonstrate that protein-synthesis-dependent mGluR-LTD is

also affected in a mouse model of RTT. Although hippocampal

mGluR-LTD per se may not be a core mechanism for the expres-

sion of ASD or ID, it has proven to be a very sensitive assay to

study postsynaptic protein translation regulation. Together,

test results from hippocampal CA1 neurons, revealing robust up-

regulation of long genes, are remarkably consistent with the find-

ings from multiple gene expression datasets using various crude

brain tissue lysates (Gabel et al., 2015). Our data support the

confirmation that the derepression of long genes occurs

specifically in excitatory hippocampal neurons in RTT mice. This

underscores the power of studying cell-type-specific translating

mRNAs, which bypasses the difficulty of deducing neuronal spe-

ific signals from mixed cell populations from brain tissue.

The significant overlap between MeCP2-repressed genes and

FMRP direct targets suggests that MeCP2 and FMRP might regulate

a common group of mRNAs at the transcriptional and translation levels,

respectively. Functional annotations of MeCP2-repressed/

FMRP direct target genes revealed multiple genes involved in cyto-

skeleton organization and cell morphogenesis. For example, Myh10,

Myyo5a, Myo18a, Dynclin1, Kif1a, Ank2, and Ank3 play key roles in

activities such as transport of synaptic vesicles, spine morphology, and

dynamics. Importantly, a significant part of MeCP2-repressed/

FMRP direct target genes belong to SFARI genes that have direct

implications in ASDs (e.g., Ank2, Ank3, Dcam, Dist, Herc2, Rehn,

and Wdyf3, etc.). Signaling via mGluR5 has been implicated in the patho-

physiology of fragile X and a number of disorders that manifest as ASD

(Wenger et al., 2016). We find that the majority of MeCP2-repressed

genes (both FMRP targets and non-FMRP targets) as a

gene set may be tuned down by chronic CTEP treatment, establish-

ing a potential mechanistic link between MeCP2-dependent trans-

cription repression and mGluR-dependent translation regulation.
Further investigation is needed to address the biological functions of those individual target genes.

Our TRAP-seq result provides a snapshot of mRNAs actively engaged with ribosomes and presumably undergoing active translation, likely reflecting the translational level regulation by MeCP2. The data support the conclusion that MeCP2 represses transcription preferentially on a group of long genes in hippocampal CA1 neurons and offers an explanation for the slight increase in basal translation observed in hippocampal slices from the KO. The TRAP-seq result by itself, however, cannot be taken as indicative of translational efficiency because it does not provide quantitative ribosome occupancy information as ribosome profiling does in cultured cells, which requires much larger input materials (Li et al., 2014). Furthermore, protein synthesis regulation is tightly regulated by neural activity (Ebert and Greenberg, 2013) and, in addition to the increased protein synthesis observed here, the hippocampus from Mecp2 KO mice shows increased network excitability (Calfa et al., 2011, McLeod et al., 2013). In contrast, hESC-derived MeCP2 mutant neurons in culture show a global downregulation of transcription and translation and hyperactivity (Li et al., 2013). Because Mecp2 KO mice display increased or decreased activity level among different brain regions as measured by the immediate early gene c-fos (Kron et al., 2012), it is likely that protein synthesis level may also exhibit brain region variation.

Recent work reported that the mTOR/AKT signaling pathway was impaired in Mecp2 KO mice as well as in cultured human embryonic stem cell-derived RTT neurons (Ricciardi et al., 2011, Li et al., 2013). Insulin-like growth factor 1 (IGF-1) was reported to alleviate a variety of symptoms in Mecp2 KO mice by enhancing the mTOR/AKT pathway (Trepoa et al., 2009, Castro et al., 2014). Although we did not observe downregulation of the AKT signaling pathway in our Mecp2 mouse colony, it is interesting to note that increasing mTOR signaling can ameliorate excessive mGluR5-dependent protein synthesis in fragile X (Auerbach et al., 2011, Bhakar et al., 2012) and could function similarly in RTT.

Excessive protein synthesis in fragile X is also corrected by chronic inhibition of mGluR5 using CTEP (Michalon et al., 2012). In the Mecp2 KO mice, we found that chronic low-dose CTEP treatment prolongs lifespan, mildly ameliorates IA deficits, and rescues the reduced soma size of hippocampal CA1 neurons. Further work needs to address the possible effects of CTEP treatment beyond the hippocampus; for example, the cardiorespiratory system, which has more direct relevance to general health. However, the limited effect of CTEP treatment on most of the other behavioral and cognitive aspects of the RTT mouse model highlights the challenge of identification and correction of the widespread core deficits of RTT.

References


